GlycoMimetics, Karyopharm Join Biotech IPO Queue

Oct 08, 2013

fiercebiotech.com

Two more biotechs are hoping to raise substantial funds for their R&D work while investors remain interested in the potential rewards of drug development.

So far this year 38 biotechs have gone public raising $2.8 billion.

Karyopharm Therapeutics, a clinical-stage pharmaceutical company, is focused on its lead anticancer contender, Selinexor. GlycoMimetics, has completed a mid-stage trial of its lead therapy, GMI-1070, which is aimed at rare cases of vaso-occlusive crisis triggered by sickle cell disease. Read more

Join the discussion

We welcome your thoughtful comments. Please comply with our Community rules.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments